Tofacitinib: a lesson in heart-immune health
When the FDA put a black box warning on tofacitinib in 2021, the message was blunt: more heart attacks, more cancers, and more blood clots. The warning came from the ORAL Surveillance trial, which followed over 4,000 patients with rheumatoid arthritis already at high cardiovascular risk. Compared to TNF blockers, patients on tofacitinib had:
- Heart attacks and strokes: About one extra event for every 111 patients treated over four years.
…